This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Espervita Therapeutics, Inc.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Innovations by Gregory R. Steinberg
Introduction
Gregory R. Steinberg is an accomplished inventor based in Ancaster, Canada. He has made significant contributions to the field of medical science, particularly in the treatment of kidney diseases and fibrosis. With a total of two patents to his name, Steinberg's work is paving the way for innovative therapeutic solutions.
Latest Patents
Steinberg's latest patents focus on functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their derivatives. These inventions provide methods for treating or preventing various kidney diseases and fibrosis, including chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis. The patents detail the use of specific compounds and their pharmaceutically acceptable salts and solvates, offering promising avenues for medical treatment.
Career Highlights
Steinberg is currently associated with Espervita Therapeutics, Inc., where he continues to develop innovative solutions in the healthcare sector. His work is characterized by a commitment to addressing critical health issues through scientific research and development.
Collaborations
Some of his notable coworkers include Daniela Carmen Oniciu and Spencer Heaton, who contribute to the collaborative environment at Espervita Therapeutics, Inc. Their combined expertise enhances the potential for groundbreaking advancements in medical treatments.
Conclusion
Gregory R. Steinberg's contributions to the field of medical science through his patents and collaborative efforts highlight his dedication to improving health outcomes. His innovative approaches are set to make a significant impact in the treatment of kidney diseases and fibrosis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile